Applied therapeutics alert: bragar eagel & squire, p.c. is investigating applied therapeutics, inc. on behalf of applied therapeutics stockholders and encourages investors to contact the firm

New york--(business wire)--bragar eagel & squire, p.c., a nationally recognized stockholder rights law firm, is investigating potential claims against applied therapeutics, inc. (“applied therapeutics” or the “company”) (nasdaq: aplt) on behalf of applied therapeutics stockholders. our investigation concerns whether applied therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices. click here to participate in the action. on january 3, 2022, applied therapeutics issued a press release “provid[ing] a regulatory update on the at-007 galactosemia program.” in the press release, applied therapeutics announced that “[f]ollowing discussions with the fda at the end of the year, the company has decided to hold on submitting an nda for at-007 for treatment of galactosemia pending additional discussions with the agency. although the galactosemia program had previously been discussed in the context of an nda for accelerated approval based on reduction in galactitol, the fda has now indicated that clinical outcomes data will likely be required for approval.” on this news, applied therapeutics’ stock price fell $1.77 per share, or 28.46%, over the following two trading sessions, closing at $4.45 per share on january 5, 2022. if you purchased or otherwise acquired applied therapeutics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact brandon walker or alexandra raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. there is no cost or obligation to you.
APLT Ratings Summary
APLT Quant Ranking